By Olivia Bugault 
 

Roche Holding AG said Thursday that its Phase 2/3 trial of Covid-19 treatment Ronapreve met its primary endpoint.

Results from the trial show that Ronapreve, which is a combination of two antibodies, casirivimab and imdevimab, "significantly" reduces the viral load within seven days in patients who have been hospitalized with Covid-19, the pharmaceutical company said.

"The efficacy and safety of Ronapreve have been studied across multiple Phase III clinical trials in non-hospitalized and hospitalized Covid-19 patients, and in the preventive setting," Roche said. "Ronapreve is currently not authorized in patients who are hospitalized due to Covid-19 infection," it said.

 

Write to Olivia Bugault at olivia.bugault@wsj.com

 

(END) Dow Jones Newswires

September 30, 2021 01:37 ET (05:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Roche (QX) Charts.